Beyond The Numbers: 7 Analysts Discuss Molina Healthcare Stock

Molina Healthcare (MOH) has received mixed analyst ratings over the last three months, with an average price target of $382.0, representing a 12.19% increase from the previous average. Recent analyst actions include Barclays lowering their price target while Bernstein, Baird, Truist Securities, Mizuho, and Wells Fargo raised their targets, reflecting varied perspectives on the company's outlook. Molina's revenue growth of 12.24% as of March 31, 2025, trails the healthcare sector average, while its ROE and ROA outperform industry averages, and its debt-to-equity ratio indicates sound financial structure.

Analysis

Molina Healthcare has attracted varied analyst perspectives over the last three months, with a sentiment distribution leaning towards cautiously optimistic, comprising one 'Bullish', three 'Somewhat Bullish', and three 'Indifferent' ratings, and notably, no 'Bearish' assessments. The average 12-month price target has risen by 12.19% to $382.0, supported by upward revisions from multiple firms including Bernstein's 'Outperform' initiation at $414 and raises from Truist, Mizuho, and Wells Fargo, although Barclays tempered its target to $351 while maintaining 'Equal-Weight'. Financially, Molina reported a 12.24% revenue growth as of March 31, 2025, a positive figure yet below the healthcare sector's average. The company's net margin of 2.67% trails industry benchmarks, signaling potential profitability pressures. However, Molina excels in operational efficiency, evidenced by an ROE of 6.77% and an ROA of 1.86%, both surpassing industry averages, complemented by a healthy debt-to-equity ratio of 0.87, indicating a solid financial structure despite its relatively smaller market capitalization.

Key Decisions for Investors

• Consider the prevailing analyst sentiment which, despite a recent neutral rating, shows an average price target increase of 12.19% and several 'Outperform' or 'Buy' ratings, suggesting potential upside for Molina Healthcare.
• Closely monitor Molina Healthcare's initiatives to improve its net margin of 2.67%, as enhanced profitability is key to fully capitalizing on its strong ROE (6.77%), ROA (1.86%), and sound debt management.
• Evaluate the company's growth prospects within its Medicaid-focused business model, particularly its 12.24% revenue growth rate against the broader healthcare sector, in conjunction with its demonstrated operational efficiencies and any potential impacts from evolving healthcare policies.